ATE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.79%

Insider Buying (Last 12 Months): C$29,400.00

Insider Selling (Last 12 Months): C$0.00

Antibe Therapeutics Insider Trading History Chart

Antibe Therapeutics Share Price & Price History

C^$0.47

▼ -0.01 (-2.11%)

As of 09/22/2023 01:00 AM ET

Days: 30 | 90 | 365

No Matter The Market, Options Trading Could Earn You More

From Tradewins | Ad

There’s no way to predict Wall Street’s future, but by using options trading, you have the opportunity to take advantage of any trend. Expert Wendy Kirkland explains how in her latest free guide.

Download it for free here!

Antibe Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2022	Daniel Marcel Legault	Director	Buy	40,000	C$0.49	C$19,400.00	983,296
11/15/2022	Scott Wilson Curtis	Senior Officer	Buy	20,000	C$0.50	C$10,000.00	100,000
7/15/2022	John Lawrence Wallace	Director	Sell	5,000	C$0.62	C$3,100.00	1,772,976
7/11/2022	Daniel Marcel Legault	Director	Buy	7,500	C$0.60	C$4,500.00	888,796
7/8/2022	Scott Wilson Curtis	Senior Officer	Buy	20,000	C$0.62	C$12,400.00	80,000
7/7/2022	John Lawrence Wallace	Director	Sell	21,500	C$0.62	C$13,330.00	1,899,576
11/10/2021	Walter Minnes Macnee	Director	Buy	50,000	C$0.90	C$45,000.00	497,027
11/3/2021	Walter Minnes Macnee	Director	Buy	25,000	C$0.98	C$24,385.00	447,027
11/1/2021	Daniel Marcel Legault	Director	Buy	2,500	C$0.92	C$2,300.00	778,796
11/1/2021	Scott Wilson Curtis	Senior Officer	Buy	13,000	C$0.88	C$11,440.00	60,000
8/4/2021	Daniel Marcel Legault	Director	Buy	12,500	C$1.02	C$12,750.00	776,296
7/14/2021	Scott Wilson Curtis	Senior Officer	Buy	2,600	C$3.42	C$8,892.00	37,000
7/13/2021	Daniel Marcel Legault	Director	Buy	4,000	C$3.57	C$14,280.00	763,796
6/30/2021	Daniel Marcel Legault	Director	Buy	4,000	C$3.70	C$14,800.00	759,796
6/3/2021	Daniel Marcel Legault	Director	Sell	75,000	C$4.00	C$300,300.00	755,796
9/24/2020	David James Vaughan	Senior Officer	Buy	52,500	C$0.34	C$17,850.00	52,500

No Matter The Market, Options Trading Could Earn You More

From Tradewins | Ad

There’s no way to predict Wall Street’s future, but by using options trading, you have the opportunity to take advantage of any trend. Expert Wendy Kirkland explains how in her latest free guide.

Download it for free here!

SEC Filings (Institutional Ownership Changes) for Antibe Therapeutics (TSE:ATE)

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Today's Range

Now: C$0.47

C$0.47

C$0.50

50 Day Range

MA: C$0.52

C$0.43

C$0.59

52 Week Range

Now: C$0.47

C$0.41

C$0.69

Volume

81,569 shs

Average Volume

27,499 shs

Market Capitalization

C$24.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17

Who are the company insiders with the largest holdings of Antibe Therapeutics?: Antibe Therapeutics' top insider investors include:
John Lawrence Wallace (Director)
Daniel Marcel Legault (Director)
Walter Minnes Macnee (Director)
Scott Wilson Curtis (Senior Officer)
Learn More about top insider investors at Antibe Therapeutics.